Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Q4: sales growth of 10.3% at CER 1 and business EPS 2 of €1.31 Pharma launches ...

(1) The presented figures and percentages are subject to rounding adjustments, which may cause discrepancies between the sum of the individual figures and the presented aggregated column and row ...

Q4 sales growth of 13.3% at CER 1 and business earnings per share (EPS) 2 of €1.53 In 2026, sales are expected to grow by a high single-digit percentage at CER. Business EPS at CER is expected to grow ...

“GF delivered a strong fourth quarter, with revenue, gross margin, operating margin and earnings per share at or above the high end of the guidance ranges,” said Tim Breen, CEO of GF. “As a result of ...

Shares of GlobalFoundries (GFS) climbed about 3% on Tuesday after the second quarter outlook beat analysts' estimates. Q1 ...

Highlights Net revenue of $1.7 billion, an increase of 9.1% compared to Q1 2025Adjusted EBITDA1 increase of 13.8% to $287.0 million and adjusted EBITDA margin1 of 16.9%, a 70 basis point increase over ...

Pharma launches increased sales by 39.8%, reaching €0.9 billion, driven by ALTUVIIIO Dupixent sales increased by 21.1% to €3.8 billion, supported by the COPD launch Vaccines sales increased by 10.3% ...

LONDON--(BUSINESS WIRE)--Endava plc (NYSE: DAVA) ("Endava" or the "Company"), a leading technology services company combining world-class engineering, industry expertise and a people-centric mindset, ...

Stantec reports first quarter 2026 results, achieving record backlog of $9.0 billion, and adjusted earnings per share growth of 14.7% Net revenue of $1.7 billion, an increase of 9.1% compared to Q1 ...